Switch theme
Sign up to access all valuation multiples
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
2021
24.6K+
LTM Revenue $15.1B
LTM EBITDA $3.8B
$60.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haleon has a last 12-month revenue (LTM) of $15.1B and a last 12-month EBITDA of $3.8B.
In the most recent fiscal year, Haleon achieved revenue of $15.1B and an EBITDA of $3.5B.
Haleon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haleon valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $15.1B | XXX | $15.1B | XXX | XXX | XXX |
| Gross Profit | $9.4B | XXX | $9.2B | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $3.8B | XXX | $3.5B | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $3.3B | XXX | $3.0B | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $2.1B | XXX | $1.9B | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $10.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Haleon's stock price is GBP 4 (or $6).
Haleon has current market cap of GBP 37.4B (or $50.2B), and EV of GBP 45.3B (or $60.8B).
See Haleon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.8B | $50.2B | XXX | XXX | XXX | XXX | $0.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Haleon has market cap of $50.2B and EV of $60.8B.
Haleon's trades at 4.0x EV/Revenue multiple, and 17.2x EV/EBITDA.
Equity research analysts estimate Haleon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haleon has a P/E ratio of 24.4x.
See valuation multiples for Haleon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50.2B | XXX | $50.2B | XXX | XXX | XXX |
| EV (current) | $60.8B | XXX | $60.8B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 16.0x | XXX | 17.2x | XXX | XXX | XXX |
| EV/EBIT | 18.2x | XXX | 20.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.4x | XXX | 25.9x | XXX | XXX | XXX |
| EV/FCF | 24.6x | XXX | 22.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHaleon's last 12 month revenue growth is 2%
Haleon's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Haleon's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haleon's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Haleon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haleon acquired XXX companies to date.
Last acquisition by Haleon was XXXXXXXX, XXXXX XXXXX XXXXXX . Haleon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Haleon founded? | Haleon was founded in 2021. |
| Where is Haleon headquartered? | Haleon is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Haleon have? | As of today, Haleon has 24.6K+ employees. |
| Who is the CEO of Haleon? | Haleon's CEO is Mr. Brian James McNamara. |
| Is Haleon publicy listed? | Yes, Haleon is a public company listed on LON. |
| What is the stock symbol of Haleon? | Haleon trades under HLN ticker. |
| When did Haleon go public? | Haleon went public in 2022. |
| Who are competitors of Haleon? | Similar companies to Haleon include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Haleon? | Haleon's current market cap is $50.2B |
| What is the current revenue of Haleon? | Haleon's last 12 months revenue is $15.1B. |
| What is the current revenue growth of Haleon? | Haleon revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Haleon? | Current revenue multiple of Haleon is 4.0x. |
| Is Haleon profitable? | Yes, Haleon is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haleon? | Haleon's last 12 months EBITDA is $3.8B. |
| What is Haleon's EBITDA margin? | Haleon's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Haleon? | Current EBITDA multiple of Haleon is 16.0x. |
| What is the current FCF of Haleon? | Haleon's last 12 months FCF is $2.5B. |
| What is Haleon's FCF margin? | Haleon's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Haleon? | Current FCF multiple of Haleon is 24.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
